¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"NORMAL SALINE CHW INFU.AMP."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • normal dwarf
    ±ÕÇü³­ÀïÀÌ, Á¤»ó³­ÀïÀÌ
  • normal endometrium
    Á¤»óÀڱ󻸷, Á¤»óÀڱüӸ·
  • normal fatty acid
    Ç¥ÁØÁö¹æ»ê
  • normal flora
    Á¤»ó±Õ¹«¸®
  • normal full term delivery
    Á¤»ó¸¸±âºÐ¸¸
  • normal human plasma
    Á¤»ó»ç¶÷Ç÷Àå
  • normal intestinal flora
    âÀÚÁ¤»ó±Õ¹«¸®, Àå³»Á¤»ó±Õ¹«¸®
  • normal limit
    Á¤»óÇѰè
  • normal occlusion
    Á¤»ó¸Â¹°¸², Á¤»ó±³ÇÕ
  • normal opsonin
    Á¤»ó¿É¼Ò´Ñ
  • normal pressure
    Á¤»ó¾Ð, Ç¥ÁؾÐ
  • normal pressure hydrocephalus
    Á¤»ó¾Ð¹°³úÁõ, Á¤»ó¾Ð¼öµÎÁõ
  • normal retinal correspondence
    Á¤»ó¸Á¸·´ëÀÀ
  • normal serum albumin
    Á¤»óÇ÷û¾ËºÎ¹Î
  • normal singleton pregnancy
    Á¤»ó¿Üµ¿ÀÓ½Å
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • normal flora
    Á¤»ó±Õ¹«¸®
  • normal intestinal flora
    âÀÚÁ¤»ó±Õ¹«¸®
  • normal tension glaucoma
    Á¤»ó¾È¾Ð³ì³»Àå
  • half-normal solution
    ¹Ý±ÔÁ¤¾×
  • normal pressure hydrocephalus
    Á¤»ó¾Ð¹°³úÁõ, Á¤»ó¾Ð¼öµÎÁõ
  • normal limit
    Á¤»óÇѰè
  • normal
    Á¤»ó-, ³ë¸£¸»
  • normal opsonin
    Á¤»ó¿É¼Ò´Ñ
  • normal pressure
    Á¤»ó¾Ð, Ç¥ÁؾÐ
  • normal state
    Á¤»ó»óÅÂ
  • normal value
    Á¤»óÄ¡
  • normal oxidizing solution
    ±ÔÁ¤»êÈ­¾×
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • citrated normal human plasma
    Á¤»óÀα¸¿¬»ê¿°Ã·°¡Ç÷Àå.
  • common opsonin =normal o.
    Á¤»ó(ïáßÈ)¿É¼Ò´Ñ.
  • flora, normal
    Á¤»ó¼¼±ÕÃÑ
  • full term normal delivery =FTND
    ¸¸±âÁ¤»óºÐ¸¸(ػѢïáßÈÝÂØ´).
  • full term normal vaginal delivery
    ¸¸±âÁ¤»ó°æÁú½ÄºÐ¸¸.
  • half normal solution
    0.5 ±ÔÁ¤¾×(¡­Ð®ïÒäû).
  • hypothetical normal occlusion
    °¡»óÁ¤»ó±³ÇÕ(Ê£ßÌïáßÈÎáùê).
  • individual normal occlusion
    °³¼ºÁ¤»ó±³ÇÕ (ËÁàõïáßÈÎáùê).
  • last normal menstrual period (LNMP)
    ÃÖÁ¾ Á¤»ó ¿ù°æÀÏ (õÌðû ïáßÈ êÅÌèìí)
  • last normal menstrual period =LNMP
    ÃÖÁ¾Á¤»ó¿ù°æ±â(õÌðûïáßÈêÅÌèÑ¢).
  • logarithmic normal distribution
    ·Î±×Á¤±ÔºÐÆ÷, ´ë¼öÁ¤±ÔºÐÆ÷(ÊÙËøË»ËÓ̰).
  • neutral occlusion =normal o.
    Á¤»ó±³ÇÕ.
  • normal
    1.Á¤»óÀÇ 2.³óµµÀÇ ´ÜÀ§,1±×·¥´ç·®/1000ml
  • normal bacterial flora
    Á¤»ó¼¼±ÕÃÑ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SS disulfide; sacrosciatic; saline soak; saline solution; saliva sample; saliva substitute; Salmonella-...
NBS N-bromosuccinimide; National Bureau of Standards; neuroblastoma supressor; nevoid basal cell carcino...
NL neural lobe; neutral lipid; nodular lymphoma; normal; normal libido, normal limits
N/S Normal Saline
D/NS dextrose in normal saline [solution]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HTS Hypertonic saline
HSD Hypertonic saline dextran
HSS hypertonic saline solution
PBS Phosphate Buffer Saline
PBS Phosphate Buffered Saline
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute and late normal tissue effects£¨Á¤»ó Á¶Á÷ ±Þ¼º ¿µÇ⣩

    acute angle

    ¿¹°¢
    Á÷°¢º¸´Ù ÀÛÀº °¢.
  • citrated normal human plasma
    Á¤»óÀÎ ±¸¿¬»ê¿° ÷°¡ Ç÷Àå
  • individual normal occlusion
    °³¼º Á¤»ó ±³ÇÕ
    Á¤»ó º¯À̳»¿¡ ÀÖ´Â °³ÀÎÂ÷¸¦ ÀÎÁ¤ÇÏ´Â Á¤»ó±³ÇÕ
  • normal adrenal function
    Á¤»óÀûÀÎ ºÎ½Å ±â´É
  • normal bacteriolysin
    Á¤»ó ¿ë±Õ¼Ò
  • normal curve
    Á¤»ó °î¼±, Á¤±Ô °î¼±
  • normal distribution
    Á¤±Ô ºÐÆ÷
  • normal eruption process
    Á¤»ó ¸ÍÃâ °úÁ¤
  • normal flora
    Á¤»ó ±ÕÃÑ, Á¤»ó ±ÕÃѱº
  • normal immunoglobulin
    Á¤»ó ¸é¿ª
  • normal occlusion
    Á¤»ó ±³ÇÕ
  • normal potential
    Á¤»ó ÀüÀ§
  • normal pressure hydrocephalus
    Á¤»ó¾Ð ¼öµÎÁõ
  • normal sinus rhythm
    Á¤»ó µ¿¹æ °áÀý ¸®µë
  • normal value
    Á¤»óÄ¡, Ç¥ÁØÄ¡, ±ÔÁ¤Ä¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
cyclic AMP receptor protein A transcriptional regulator in prokaryotes which, when activated by binding cyclic AMP, acts at several promoters. Cyclic AMP receptor protein was originally identified as a catabolite gene activator protein. It was subsequently shown to regulate several functions unrelated to catabolism, and to be both a negative and a positive regulator of transcription. Cell surface cyclic AMP receptors are not included (cyclic AMP receptors), nor are the eukaryotic cytoplasmic cyclic AMP receptor proteins, which are the regulatory subunits of cyclic AMP-dependent protein kinases.
(12 Dec 1998)
dibutyryl cyclic AMP An analogue of cyclic AMP that shares some of the pharmacological effects of this nucleotide, but is generally believed to enter cells more readily on account of its greater hydrophobicity.
(18 Nov 1997)
DNA-binding protein, cyclic AMP-responsive A protein that has been shown to function as a calcium regulated transcription factor as well as a substrate for depolarisation-activated calcium calmodulin-dependent protein kinases I and II. This protein functions to integrate both calcium and camp signals.
(12 Dec 1998)
2,3-dihydroxybenzoate-AMP ligase <enzyme> Catalyses the conversion of 2,3-dihydroxybenzoate and ATP to form (2,3-dihydroxybenzoyl)adenylate, this acyladenylate remains bound to the enzyme for further reactions in the overall biosynthesis of enterobactin
Registry number: EC 6.5.-
Synonym: 2,3dhb-AMP ligase, ente gene product
(26 Jun 1999)
3',5'-cyclic AMP synthetase <enzyme> Enzyme responsible for the ATP.
(06 May 1997)
3-hydroxypicolinic acid-AMP ligase <enzyme> From cell extracts of streptomyces pristinaespiralis; activates the first pristinamycin 1 residue 3-hydroxypicolinic acid; shows 58% nh2-terminal amino acid sequence identity with s. Griseoviridus 3-hpa-activating enzyme; amino acid sequence given in first source (page 709)
Registry number: EC 6.3.2.-
Synonym: pi synthetase 1, snba protein, pristinamycin I synthetase 1,3-hpa-AMP ligase
(26 Jun 1999)
L-phenylglycine-AMP ligase <enzyme> Catalyses l-phenylglycine-dependent ATP-pyrophosphate exchange; partial amino acid sequence given in first source
Registry number: EC 6.3.2.-
Synonym: pristinamycin I synthetase 4, pi synthetase 4, snbe protein
(26 Jun 1999)
beta-normal <radiobiology> Beta-N, the normalised beta, is beta relative to the beta limit.
(09 Oct 1997)
big axillary nodes and normal breasts <radiology> Consider: lymphoma, leukaemia, rheumatoid arthritis
(12 Dec 1998)
gallium uptake with normal chest film <radiology> Pulmonary drug toxicity, tumour infiltration, sarcoidosis, pneumocystis carinii see: lung: gallium imaging
(12 Dec 1998)
range, normal Normal results can fall outside the normal range. By convention, the normal range is set to cover ninety-five percent (95%) of values from a normal population. Five percent (5%) of normal results therefore fall outside the normal range.
(12 Dec 1998)
human normal immunoglobulin A preparation of the proteins of liquid human plasma, containing the antibodies of normal adults; it is obtained from pooled liquid human plasma from a number of donors and may be prepared by precipitation with organic solvents under controlled conditions of pH, ionic strength, and temperature.
Synonym: human normal immunoglobulin.
(05 Mar 2000)
normal <microscopy> An imaginary line forming a right angle with the tangent to a curved surface at a particular point. It is used as a basis for determining angles of incidence, reflection, and refraction.
(05 Aug 1998)
normal animal In research, an experimental animal that has neither suffered an attack of a particular disease nor received an injection of a specific microorganism or its toxin.
(05 Mar 2000)
normal antibody Antibody demonstrable in the serum or plasma of various persons or animals not known to have been stimulated by specific antigen, either artificially or as the result of naturally occurring contact.
Synonym: natural antibody.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á